crinetics pharmaceuticals san diego logo web
  • Pipeline
    • Research Pipeline
    • Paltusotine
    • CRN04777, Oral SST5 Agonist
    • CRN04894, Oral ACTH Antagonist
    • Oral PTH Antagonist
  • Patients
    • Clinical Trials
    • Patient Videos
      • Clinical Trials
      • Acromegaly in a Pandemic
      • Acromegaly Symptoms
      • Acromegaly Diagnosis
      • Acromegaly Advocate
      • Acromegaly Support
    • PATHFNDR
  • Professionals
    • Acromegaly
    • Congenital Hyperinsulinism
    • Carcinoid Syndrome
    • PATHFNDR
  • Investors
    • Overview
    • Corporate Presentation
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Analyst Coverage
    • Investor Resources
  • About Us
    • Employee Spotlight
    • Community
  • Careers
    • Culture
    • Job Listings
    • Benefits
  • Contact
    • Contact Us
    • Partnering
    • Grants and Funding
https://crinetics.com/wp-content/uploads/2022/01/808-rotation-d3-header-optimized.mp4

acromegaly awareness day 2021 slider preview CRC


https://crinetics.com/wp-content/uploads/2022/01/crnx-homepage-full-optimized.mp4

Better therapies.Better lives.

Pipeline >


Phase 3 studies of paltusotine for acromegaly

For HCPsFor Patients

Be Your Own Advocate

Acromegaly patients share the importance of being your own advocate.

Watch Our Video
acromegaly-awareness-2020-acromegaly-advocate

A fuller, freer life is within reach.


Living with a rare endocrine disease can be challenging. We’re working on new treatments to these life-threatening conditions that you need and deserve. Like an oral treatment for acromegaly called paltusotine, which will be a welcome development for many patients and their families.

Read About Our Studies

A company as rare as the diseaseswe focus on.


Few companies focus exclusively on endocrine diseases. We do. Many patients have longed for better therapies that offer symptom improvement and a better quality of life. We’re innovating to try to make this happen. Bringing cutting-edge science to underserved patients is important work. We do it every day.

Learn More About Us

We've built a better workplace to help patients build better lives.


“Focused intensity” is how we like to describe our approach to our jobs. There’s a lot of work to do when you’re trying to improve patients’ lives. Lots of discoveries to make. Lots of goals to meet. But we love the challenges and embrace them head-on. Intrigued?

Explore Working Here

Better therapies.Better lives.

Pipeline >


Phase 3 studies of paltusotine for acromegaly

For HCPsFor Patients

Be Your Own Advocate

Acromegaly patients share the importance of being your own advocate.

Watch Our Video

A fuller,freer life iswithin reach.


Living with a rare endocrine disease can be challenging. We’re working on new treatments to these life-threatening conditions that you need and deserve. Like an oral treatment for acromegaly called paltusotine, which will be a welcome development for many patients and their families.

Read About Our Studies

A company as rare as the diseaseswe focus on.


Few companies focus exclusively on endocrine diseases. We do. Many patients have longed for better therapies that offer symptom improvement and a better quality of life. We’re innovating to try to make this happen. Bringing cutting-edge science to underserved patients is important work. We do it every day.

Learn More About Us

We've built a better workplace to help patients build better lives.


“Focused intensity” is how we like to describe our approach to our jobs. There’s a lot of work to do when you’re trying to improve patients’ lives. Lots of discoveries to make. Lots of goals to meet. But we love the challenges and embrace them head-on. Intrigued?

Explore Working Here

Subscribe


The Better Bulletin, our periodic newsletter, helps you stay informed on our work to improve the lives of patients living with rare endocrine diseases.

Add Me
Name
Hidden
Confirmation(Required)
This field is for validation purposes and should be left unchanged.
crinetics logo full uai
  • Pipeline
  • Patients
  • Professionals
  • Press
  • Financials
  • Presentation
  • Events
  • Contact
  • Partnering
  • Careers
  • Culture
  • Job Listings
  • About
  • Terms
  • Privacy

  • Crinetics Facebook
  • Crinetics Twitter
  • Crinetics LinkedIn

(858) 450-6464 · 10222 Barnes Canyon Road, Building 2, San Diego, CA 92121
Crinetics Pharmaceuticals, Inc. © 2023 All rights reserved

crinetics logo full uai

  • Pipeline
  • Patients
  • Professionals
  • Financials
  • Presentation
  • Press
  • Events
  • Careers
  • Culture
  • Job Listings
  • About
  • Contact
  • Partnering
  • Privacy
  • Terms
  • Pipeline
  • Patients
  • Professionals
  • Presentation
  • Partnering
  • Financials
  • Press
  • About
  • Contact
  • Careers
  • Privacy
  • Terms

  • Crinetics Facebook
  • Crinetics Twitter
  • Crinetics LinkedIn

(858) 450-6464

10222 Barnes Canyon Road, Building 2,
San Diego, CA 92121

Crinetics Pharmaceuticals, Inc.
© 2023 All rights reserved

Medical Education Grant Application

"*" indicates required fields

MM slash DD slash YYYY
Address*
Therapeutic Area (TA)
Type of Grant

Key Points for Consideration

If your request for support is approved, you will be required to enter into a written grant agreement with Crinetics. Crinetics has drafted the terms of its agreement to be balanced, reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution is able and willing to abide by standard agreement terms before proceeding with submission of your application as they will need to be accepted to proceed.
Max. file size: 50 MB.
Signed and dated on your organization’s letterhead

Investigator-Initiated Research Study Application

"*" indicates required fields

MM slash DD slash YYYY
Address*
Therapeutic Area (TA):

Key points for Consideration

If your request for support is approved, you will be required to enter into a written grant agreement with Crinetics. Crinetics has drafted the terms of its agreement to be balanced, reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution is able and willing to abide by standard agreement terms before proceeding with submission of your application as they will need to be accepted to proceed.
Max. file size: 50 MB.
Signed and dated on your organization’s letterhead